New drug combo targets tough leukemia in early trial
NCT ID NCT07355335
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests two oral drugs, ziftomenib and mezigdomide, given together to adolescents and adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial focuses on people whose leukemia has specific genetic changes (KMT2A rearrangement or NPM1 mutation). The main goals are to check safety and find the best dose, with only 24 participants planned.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ziftomenib (KO-539) and mezigdomide (CC-92480) taken as oral capsules
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for people with certain types of AML that have not responded to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 24 participants, so the main goal is safety, not effectiveness. The combination may cause side effects or fail to control the leukemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KMT2A-REARRANGED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.